The Portfolia team is hosting a live investor overview session on May 21 at 1:00 PM PST, led by Trish Costello, CEO & Founder of Portfolia, and Dawn Mattoon, PhD, CEO of Mercy Bio. [RSVP below to attend.]
This is a rare opportunity to join the cap table of a company with:
FDA Breakthrough Device Designation for its Mercy Halo™ assay, a first-of-its-kind blood test that detects ovarian cancer at the earliest—and most treatable—stages.
Unprecedented clinical performance: 89% sensitivity and 98% specificity for detecting high-grade serous ovarian cancer in asymptomatic, postmenopausal women.
A $29B+ market opportunity across ovarian and lung cancer screening, aided by bipartisan support for reimbursement under the Multicancer Early Detection (MCED) Act.
High-margin, low-cost testing with over 70% gross margin at $300/test and potential for >75% at scale with reimbursement pricing.
An extensible platform targeting multiple cancer types with a simple, qPCR-based workflow compatible with global lab infrastructure.
DO NOT DISCUSS OR FORWARD INFORMATION.
The allocation is limited. Signed commitments will be reviewed as received. Commitments must be received by June 6.CONFIDENTIALITY NOTICE:
As a Portfolia member, you sign a confidentiality agreement as part of our investing agreement. However, when evaluating a direct investment, you have access to highly confidential materials that can not be disclosed to others. If you wish to access the data room, you will be required to e-sign a binding non-disclosure agreement. All information is confidential including that the company is currently conducting a private fundraise and its valuation, as well as all materials covered in the data room. In accessing the materials, you are also attesting that you do not work for or have a financial interest or connection to any other company that could be deemed a competitor to Mercy Bio.
Portfolia does not make investment recommendations, and no communication should be construed as a recommendation for any offer of a security referenced here or otherwise. All investors in Portfolia Funds must be accredited investors. Investing in private placements requires high tolerance for risk and illiquidity, and investors must be able to afford to lose their entire investment.Information about any securities offering should not be considered complete and is qualified by the full offering documents corresponding to the financing. The information contained here or in any correspondence or attachment hereto may include forward-looking statements, estimates, projections and/or representations. To the fullest extent permissible by law, neither Portfolia, Inc. nor its funds; nor any of their managers or non-managing members, employees, representatives, or agents make any representation or warranty, express or implied, as to the accuracy, completeness or definitiveness of this information, and nothing contained herein shall be relied upon as a representation as to past or future performance. We are not a registered broker, dealer, investment advisor, investment manager or funding portal. Portfolia Inc. and Portfolia Managing Member do not give investment advice, provide analysis or recommendations. Please note a fund’s past performance is not indicative of future results.
